Search Results
Mar 19, 2026, 22:29 ET Basecamp Research lança Trillion Gene Atlas para ampliar terapias desenvolvidas por IA
o lançamento do Trillion Gene Atlas, uma iniciativa científica histórica para gerar e modelar dados biológicos na escala de um trilhão de genes. Lançado em colaboração com Anthropic, Ultima Genomics e PacBio, e alimentado pela infraestrutura de IA da NVIDIA, o Trillion Gene Atlas visa expandir a diversidade
More news about: Basecamp Research
Mar 19, 2026, 22:26 ET Basecamp Research presenta Trillion Gene Atlas para escalar la terapia diseñada por IA
laboratorio de IA de vanguardia de diseño biológico, anunció el lanzamiento de Trillion Gene Atlas, una iniciativa científica histórica para generar y modelar datos biológicos a escala de billones de genes. Trillion Gene Atlas se lanzó en colaboración con Anthropic, Ultima Genomics y PacBio, está impulsado
More news about: Basecamp Research
Mar 19, 2026, 22:04 ET Basecamp Research 推出 Trillion Gene Atlas（萬億基因組圖譜）以規模化人工智能設計療法
我們很高興本公司的技術能夠幫助 Basecamp 實現其願景，並推動像 Trillion Gene Atlas 這樣的創新計劃。」PacBio 總裁兼行政總裁 Christian Henry 表示：「PacBio HiFi 測序可提供超準確的長讀長，保留完整基因組背景，並能在複雜樣本中實現亞種甚至菌株水平的精細解像。 HiFi 數據提供資訊豐富的可靠基礎，生物人工智能模型需要這些基礎來大規模地向自然學習，並推動像 Trillion Gene Atlas 這樣的計劃。」Trillion Gene Atlas 將借助 NVIDIA 的加速運算基礎設施，來處理達到 PB 量級的龐大遺傳數據。
More news about: Basecamp Research
Mar 19, 2026, 20:05 ET RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: THE ROSEN LAW FIRM, P. A.
Mar 19, 2026, 18:57 ET Ultima Genomics Announces UG200 Series Selected for Basecamp Research's Groundbreaking Trillion Gene Atlas
design, has selected the UG200 Series as the short read sequencing platform to enable the Trillion Gene Atlas—a landmark scientific initiative designed to generate and model biological data at the trillion-gene scale. This first-of-its-kind collaboration is expected to result in the expansion of evolutionary
More news about: Ultima Genomics
Mar 19, 2026, 17:40 ET Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline
COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel gene therapy being developed to slow the progression of HD. During the Class Period, uniQure
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 19, 2026, 12:05 ET Greenland Mines Engages WSP Denmark to Launch Comprehensive Environmental Baseline Program at Skaergaard Mining Site
of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80%
More news about: Klotho Neurosciences, Inc.
Mar 19, 2026, 11:01 ET Washington Research Foundation awards $7 million to UW Institute for Protein Design for ambitious initiative to advance AI-enabled enzyme design
deep learning-enabled enzyme design capabilities by improving its "design-build-test-learn" pipeline, to move ideas from computational design through gene synthesis and laboratory validation. Data will be collected and fed back to improve the team's AI models, with the goal of developing predictive tools
More news about: WASHINGTON RESEARCH FOUNDATION
Mar 19, 2026, 10:59 ET 'Functional Unemployment' Jumps in February; Women, Black Workers All Lose Ground, Says Ludwig Institute
@LISEP_org.About Gene LudwigIn addition to his role as LISEP chair, Gene Ludwig is a managing partner of Canapi LLC, a financial technology venture fund. He is the founder and CEO of Ludwig
More news about: Ludwig Institute for Shared Economic Prosperity
Mar 19, 2026, 10:01 ET Preimplantation Genetic Testing Market to Reach US$ 1,081.9 Million by 2033 Amid Rising IVF Adoption and Technological Innovation - Persistence Market Research
HybridizationBy ApplicationAneuploidyX-Linked DisordersStructural Chromosomal AbnormalitiesSingle Gene DisordersGender IdentificationHLA Typing for Stem Cell TransplantsBy Distribution ChannelHospitalsFertility
More news about: Persistence Market Research Pvt. Ltd.
Mar 19, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
2026, Regenxbio issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Pomerantz LLP
Mar 19, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently
More news about: Pomerantz LLP
Mar 19, 2026, 10:00 ET Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
window for companies with asymmetric upside in high-value solid tumor markets, as the FDA's expanded accelerated approval framework—now covering gene therapies and next-generation combination regimens—compresses the timeline from translational data to commercial launch, making regulatory milestones
More news about: USA News Group
Mar 19, 2026, 09:00 ET STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP
Medical Officer, is named as an individual defendant in a securities class action alleging that his repeated public assurances about the safety of RGX-111 gene therapy concealed material risks from investors. When the truth emerged on January 28, 2026, RGNX shares fell $2.40 per share, a decline of 17.8%, closing
More news about: SueWallSt.com
Mar 19, 2026, 09:00 ET Congruence Announces First Dosing in Phase 1/1b Clinical Trial of CGX-926, a First-in-Class Oral MC4R Corrector for Genetic Obesity
tolerability, and pharmacokinetics of CGX-926, while also exploring preliminary efficacy in individuals with MC4R-deficient obesity. Mutations in the MC4R gene represent the most common form of genetic obesity and lead to early-onset obesity and hyperphagia (i.e., increased drive to eat).In the brain,
More news about: Congruence Therapeutics
Mar 19, 2026, 08:10 ET Ractigen Therapeutics Announces China NMPA IND Approval for Phase II Clinical Trial of saRNA Therapy RAG-01 in Non-Muscle Invasive Bladder Cancer
activation is a clinically validated platform technology developed by Dr. Long-Cheng Li and his team. It utilizes saRNAs to target gene regulatory domains, activating gene expression and restoring therapeutic protein levels. This innovative technology holds vast potential for developing therapeutic drugs
More news about: Ractigen Therapeutics
Mar 19, 2026, 06:23 ET Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China
country's first gene therapy for hemophilia B, [1] the recent approval of BBM-H901 in Macao, China, not only addresses the previously unmet medical need for such treatment in the region but also marks a crucial step in accelerating the global availability of this breakthrough gene therapy.
More news about: Belief BioMed
Mar 19, 2026, 06:00 ET AccuWeather® and the Hunt Preservation Society Partner to Support Ongoing Texas Hill Country Recovery Efforts to Improve Severe Weather Preparation and Responsiveness
KerrTogether.Media Contacts:AccuWeather – Gene Petriello [email protected] Preservation Society – Vikki
More news about: AccuWeather, Inc.
Mar 19, 2026, 03:38 ET Animal Regenerative Therapies Market Worldwide to Reach USD 870 Million by 2032, Driven by Advancements in Veterinary Biotechnology | Vyansa Intelligence
veterinary treatment solutions, and rapid advancements in regenerative medicine technologies such as stem cell therapy, platelet-rich plasma (PRP), and gene therapy.
More news about: Vyansa Intelligence
Mar 18, 2026, 21:44 ET Basecamp Research startet den Trillion Gene Atlas, um KI-entwickelte Therapeutika zu skalieren
darunter insbesondere die bahnbrechende AI-Programmable Gene Insertion (aiPGI) zum Einfügen gesunder Gene sowie die Entwicklung zielgerichteter antimikrobieller Peptide mit einer Trefferquote von 97 % gegen prioritäre Krankheitserreger.Der Trillion Gene Atlas baut auf diesem Ansatz auf, indem er die Breite
More news about: Basecamp Research
Mar 18, 2026, 18:13 ET 베이스캠프 리서치, 트릴리언 진 아틀라스 출범으로 AI 설계 치료제 확대 나서
2026년 3월 19일 /PRNewswire/ -- 생물학적 설계 전문 프런티어 AI 연구소 베이스캠프 리서치가 1조 유전자 규모로 생물학 데이터를 생성하고 모델링할 수 있는 획기적 과학 이니셔티브 트릴리언 진 아틀라스(Trillion Gene Atlas)를 출범한다고 3월 18일 발표했다. 앤트로픽, 얼티마 지노믹스, 팩바이오가 함께 하고 엔비디아 AI 인프라를 활용하는 트릴리언 진 아틀라스는 전 세계 현장 수천 곳에서 1억이 넘는 새 종의 유전체 데이터를 수집해 알려진 진화 유전 다양성을 100배 확대하는
More news about: Basecamp Research
Mar 18, 2026, 18:01 ET Basecamp Research lance le Trillion Gene Atlas pour développer des thérapies conçues par l'IA
du Trillion Gene Atlas, une initiative scientifique historique visant à générer et à modéliser des données biologiques à l'échelle du millier de milliards de gènes. Lancé en collaboration avec Anthropic, Ultima Genomics et PacBio, et alimenté par l'infrastructure NVIDIA AI, le Trillion Gene Atlas vise
More news about: Basecamp Research
Mar 18, 2026, 15:43 ET Basecamp Research、AI創薬拡大に向けた「Trillion Gene Atlas」を発表
-- 生物学的設計分野における先進的なAI研究機関であるBasecamp Researchは本日、1兆遺伝子規模で生物学データの生成およびモデリングを行う画期的な科学プロジェクトである「Trillion Gene Atlas」の立ち上げを発表しました。Anthropic、Ultima Genomics、PacBioとの協業のもと、NVIDIAのAIインフラによって支えられるTrillion Gene Atlasは、世界各地の数千の地点において1億種を超える生物種からゲノムデータを収集することで、既知の進化的遺伝的多様性を100倍に拡大することを目指しています。 これは、Basecamp
More news about: Basecamp Research
Mar 18, 2026, 15:43 ET Genome Canada and Ontario Genomics Award Specific Biologics and Western University $1.8 Million Grant to Develop a Machine Learning Platform to Accelerate the Development of the Company's Dualase®-based Therapeutics
in vivo genome editing, with an initial therapeutic focus on the precise collapse of pathogenic DNA repeat expansions including in the C9ORF72 gene, the most frequent genetic cause of amyotrophic lateral sclerosis (ALS). The unique Dualase® two-site mechanism enables the seamless removal,
More news about: Specific Biologics Inc.
Mar 18, 2026, 15:43 ET Genome Canada and Ontario Genomics Award Specific Biologics and Western University $1.8 Million Grant to Develop a Machine Learning Platform to Accelerate the Development of the Company's Dualase®-based Therapeutics
in vivo genome editing, with an initial therapeutic focus on the precise collapse of pathogenic DNA repeat expansions including in the C9ORF72 gene, the most frequent genetic cause of amyotrophic lateral sclerosis (ALS). The unique Dualase® two-site mechanism enables the seamless removal,
More news about: Specific Biologics Inc.